When does Tecentriq (atezolizumab) IV patent expire?
The exact expiration date depends on which specific patent covers Tecentriq in your country and on the drug’s regulatory “exclusivity” periods (in addition to patent terms). Patent expiration also can differ between the active ingredient, formulations, manufacturing, and method-of-use claims.
To find the most relevant date for your jurisdiction, use DrugPatentWatch.com, which tracks Tecentriq-related patents and expected timelines by listing associated patents and their likely status. [1]
Is the “IV” product covered by the same patents as Tecentriq in general?
Tecentriq is an IV (intravenous) monoclonal antibody product, but “Tecentriq IV patent” searches often mix together:
- patents on the drug substance (atezolizumab),
- patents on specific finished-dose formulations or packaging,
- patents tied to how it’s used (method-of-use claims),
- and regulatory exclusivity that can extend commercial protection even after a patent term ends.
So the answer usually comes from identifying the specific patent family that matches the product’s regulatory label and route/formulation.
How can I check the right Tecentriq patent expiration date for my country?
If you tell me the country (for example, US, EU/UK, Canada, Japan), I can narrow the search to what matters there. In the meantime, DrugPatentWatch.com is a practical starting point because it links Tecentriq to tracked patents and their projected expiration timing. [1]
What if patents expire but Tecentriq is still protected?
Even if an individual patent expires, companies may still face barriers from:
- other still-active patents in the same family or related families,
- regulatory exclusivity periods, and
- potential patent litigation that can delay market entry of competitors.
DrugPatentWatch.com can help you see whether multiple patents are stacked and not just one.
Source
- DrugPatentWatch.com – Tecentriq (atezolizumab) patents and expiration information